FDA seeks to reverse Tavneos approval over alleged data manipulation
The FDA is seeking to withdraw its approval of Tavneos after concluding that the drug was approved using manipulated study data. The decision raises questions about how regulators should correct an approval that rests on allegedly compromised evidence.
Withdrawal may not be straightforward. The process can involve additional review and opportunities for the drug’s manufacturer to respond, so a move by the FDA does not necessarily mean that Tavneos will immediately become unavailable.
For patients currently using the medication, the central concern is whether access will continue while the approval is reconsidered. The episode also underlines the importance of study-data integrity to the FDA’s assessment of a drug’s safety and effectiveness.